BRIEF published on 03/14/2025 at 07:35, 1 year 3 months ago Sensorion : Bilan 2024 et Perspectives pour 2025 Résultats Financiers Investissements Thérapies Géniques SENS-401 SENS-501
BRIEF published on 03/14/2025 at 07:35, 1 year 3 months ago Sensorion: 2024 Review and Outlook for 2025 Financial Results Investments SENS-401 SENS-501 Gene Therapies
PRESS RELEASE published on 03/14/2025 at 07:30, 1 year 3 months ago Informations privilégiées / Communiqué sur comptes, résultats Sensorion présente ses résultats financiers pour l’exercice 2024, fait le point sur ses activités et annonce la mise à disposition du rapport annuel. Renforcement financier, essais cliniques avancés Résultats Financiers Innovation Scientifique Thérapie Génique Études Cliniques Sensorion
PRESS RELEASE published on 03/14/2025 at 07:30, 1 year 3 months ago Inside Information / News release on accounts, results Sensorion reports full-year 2024 results and provides corporate update with significant milestones achieved in gene therapy clinical trials and financial highlights. Company well positioned for growth in 2025 Clinical Trials Financial Highlights Gene Therapy Full-year Results Sensorion
BRIEF published on 03/07/2025 at 07:35, 1 year 3 months ago Sensorion conclut le recrutement pour l'essai NOTOXIS sur le SENS-401 Essai Clinique Sensorion SENS-401 Cisplatine Ototoxicité
BRIEF published on 03/07/2025 at 07:35, 1 year 3 months ago Sensorion Completes Recruitment for NOTOXIS Trial of SENS-401 Clinical Trial Sensorion SENS-401 Cisplatin Ototoxicity
PRESS RELEASE published on 03/07/2025 at 07:30, 1 year 3 months ago Informations privilégiées / Autres communiqués Sensorion annonce la fin du recrutement des patients dans NOTOXIS, essai clinique Phase 2a SENS-401 pour prévenir ototoxicité cisplatine. Résultats NOTOXIS attendus fin 2025 Phase 2a Sensorion SENS-401 Ototoxicité NOTOXIS
PRESS RELEASE published on 03/07/2025 at 07:30, 1 year 3 months ago Inside Information / Other news releases Sensorion completes patient enrollment in NOTOXIS Phase 2a Clinical Trial of SENS-401 for Cisplatin-Induced Ototoxicity prevention, targeting a significant unmet medical need Clinical Trial Sensorion SENS-401 NOTOXIS Cisplatin-Induced Ototoxicity
BRIEF published on 02/21/2025 at 07:35, 1 year 4 months ago Sensorion's SENS-501 Clinical Trial Progresses with Positive DMC Recommendation Gene Therapy Clinical Trial Sensorion Hearing Loss SENS-501
BRIEF published on 02/21/2025 at 07:35, 1 year 4 months ago L'essai clinique SENS-501 de Sensorion progresse avec une recommandation DMC positive Essai Clinique Thérapie Génique Sensorion Perte Auditive SENS-501
Published on 07/03/2026 at 23:00, 23 hours 20 minutes ago Eagle Plains Partner Refined Energy Announces Final Results for Winter 2026 Drill Program at Dufferin West
Published on 07/03/2026 at 21:28, 1 day ago Trifecta Gold Announces Closing of $1.66 Million Private Placement
Published on 07/03/2026 at 19:30, 1 day 2 hours ago Polaris Renewable Energy Announces Q2 2026 Investor Call Details
Published on 07/03/2026 at 13:30, 1 day 8 hours ago Nextech3D.ai Unveils Strategic AI Growth Roadmap Focused on Workforce Intelligence and Event Technology Innovation
Published on 07/04/2026 at 17:35, 4 hours 45 minutes ago Vantage Introduces 24/7 Gold CFD Trading with XAUUSD247
Published on 07/04/2026 at 11:01, 11 hours 19 minutes ago EQS-Adhoc: Continental AG: Continental AG Sells ContiTech Group Sector
Published on 07/04/2026 at 09:05, 13 hours 15 minutes ago Velo x McLaren Mastercard Formula 1® Team Relaunches Live Your Fandom to Bring Fans Closer to the Sport They Love
Published on 07/03/2026 at 19:00, 1 day 3 hours ago PATRIMOINE ET COMMERCE: BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE AU 30 JUIN 2026
Published on 07/03/2026 at 18:55, 1 day 3 hours ago Saudia Arabia's Mabani Aljazeera Group invests in Tatu City's Jabali Towers development
Published on 07/03/2026 at 21:49, 1 day ago Safran annonce la fin des négociations concernant le projet d'acquisition d’Exail Technologies.
Published on 07/03/2026 at 21:49, 1 day ago Safran announces the end of negotiations regarding the contemplated acquisition of Exail Technologies.
Published on 07/03/2026 at 18:42, 1 day 3 hours ago Total number of voting rights and shares making up the share capital at June 30, 2026
Published on 07/03/2026 at 18:36, 1 day 3 hours ago Disclosure of transactions in own shares from July 1 to July 3, 2026
